Beijing Wantai Biological Stock Current Valuation
| 603392 Stock | 75.37 1.25 1.63% |
Valuation analysis of Beijing Wantai Biological helps investors to measure Beijing Wantai's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Beijing Wantai's Cash is projected to increase significantly based on the last few years of reporting. The current year's End Period Cash Flow is expected to grow to about 4 B, whereas Change In Cash is projected to grow to (1.3 B). Fundamental drivers impacting Beijing Wantai's valuation include:
Price Book 7.6753 | Enterprise Value 90.8 B | Enterprise Value Ebitda 848.7828 | Price Sales 38.0705 | Enterprise Value Revenue 36.458 |
Fairly Valued
Today
Please note that Beijing Wantai's price fluctuation is very steady at this time. Calculation of the real value of Beijing Wantai Biological is based on 3 months time horizon. Increasing Beijing Wantai's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Beijing Wantai is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Beijing Stock. However, Beijing Wantai's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 75.37 | Real 75.7 | Hype 75.64 |
The real value of Beijing Stock, also known as its intrinsic value, is the underlying worth of Beijing Wantai Biological Company, which is reflected in its stock price. It is based on Beijing Wantai's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Beijing Wantai's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Beijing Wantai Biological helps investors to forecast how Beijing stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Beijing Wantai more accurately as focusing exclusively on Beijing Wantai's fundamentals will not take into account other important factors: Beijing Wantai Biological Company Current Valuation Analysis
Beijing Wantai's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Beijing Wantai Current Valuation | 90.78 B |
Most of Beijing Wantai's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Beijing Wantai Biological is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Beijing Wantai Biological has a Current Valuation of 90.78 B. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The current valuation for all China stocks is significantly lower than that of the firm.
Beijing Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Beijing Wantai's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Beijing Wantai could also be used in its relative valuation, which is a method of valuing Beijing Wantai by comparing valuation metrics of similar companies.Beijing Wantai is currently under evaluation in current valuation category among its peers.
Beijing Fundamentals
| Return On Equity | -0.0226 | ||||
| Return On Asset | -0.0154 | ||||
| Profit Margin | (0.12) % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 90.78 B | ||||
| Shares Outstanding | 1.27 B | ||||
| Shares Owned By Insiders | 81.86 % | ||||
| Shares Owned By Institutions | 4.08 % | ||||
| Price To Book | 7.68 X | ||||
| Price To Sales | 38.07 X | ||||
| Revenue | 5.51 B | ||||
| Gross Profit | 9.99 B | ||||
| EBITDA | (122.77 M) | ||||
| Net Income | 1.25 B | ||||
| Total Debt | 81.14 M | ||||
| Book Value Per Share | 9.35 X | ||||
| Cash Flow From Operations | 1.54 B | ||||
| Earnings Per Share | (0.23) X | ||||
| Target Price | 61.4 | ||||
| Number Of Employees | 3.84 K | ||||
| Beta | 2.26 | ||||
| Market Capitalization | 94.8 B | ||||
| Total Asset | 15.71 B | ||||
| Retained Earnings | 7.57 B | ||||
| Working Capital | 7.63 B | ||||
| Net Asset | 15.71 B | ||||
| Last Dividend Paid | 0.32 |
About Beijing Wantai Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Beijing Wantai Biological's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Beijing Wantai using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Beijing Wantai Biological based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Beijing Stock
Beijing Wantai financial ratios help investors to determine whether Beijing Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Beijing with respect to the benefits of owning Beijing Wantai security.